Salarius Pharmaceuticals Files 8-K on Shareholder Nominations
Ticker: DCOY · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1615219
Sentiment: neutral
Topics: corporate-governance, shareholder-action
TL;DR
Salarius Pharma filed an 8-K on 9/27 for shareholder nominations - board shakeup incoming?
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on September 27, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The company, formerly known as Flex Pharma, Inc., is incorporated in Delaware and based in Houston, Texas.
Why It Matters
This filing indicates potential changes or discussions regarding the company's board composition or strategic direction driven by shareholder input.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations can signal potential activism or changes in corporate governance, which may introduce uncertainty.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former company name
- September 27, 2024 (date) — Date of report
- Exchange Act Rule 14a-11 (regulation) — Subject of filing
FAQ
What specific shareholder nominations were made?
The filing does not specify the details of the shareholder nominations, only that they are being reported pursuant to Exchange Act Rule 14a-11.
What are the 'Other Events' being reported?
The filing does not provide details on the 'Other Events' beyond mentioning them as a category of information being reported.
When was Salarius Pharmaceuticals, Inc. formerly known as Flex Pharma, Inc.?
The date of the name change from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc. was July 30, 2014.
Where is Salarius Pharmaceuticals, Inc. headquartered?
Salarius Pharmaceuticals, Inc. is headquartered at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
What is the primary business of Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 948 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-09-27 16:01:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20240927.htm (8-K) — 29KB
- 0001615219-24-000079.txt ( ) — 149KB
- flks-20240927.xsd (EX-101.SCH) — 2KB
- flks-20240927_lab.xml (EX-101.LAB) — 21KB
- flks-20240927_pre.xml (EX-101.PRE) — 12KB
- flks-20240927_htm.xml (XML) — 3KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
01. Other Events
Item 8.01. Other Events. On September 26, 2024, the Board of Directors of Salarius Pharmaceuticals, Inc. (the "Company") established December 20, 2024 as the date of the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"). The time, location, and other meeting details for the 2024 Annual Meeting will be set forth in the Company's proxy statement for the 2024 Annual Meeting, which will be filed prior to the 2024 Annual Meeting with the U.S. Securities and Exchange Commission ("SEC"). Stockholders of record at the close of business on October 25, 2024 will be entitled to notice of and to vote at the 2024 Annual Meeting or any adjournment thereof. Because the date of the 2024 Annual Meeting has been changed by more than 30 days from the anniversary of the date of the Company's last annual meeting of stockholders, in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company is informing stockholders of such change. Furthermore, new deadlines have been set for submission of proposals by stockholders intended to be presented at the 2024 Annual Meeting and included in the Company's proxy statement for the 2024 Annual Meeting. In accordance with Rule 14a-8 under the Exchange Act ("Rule 14a-8"), if a stockholder wishes to present a proposal for inclusion in the proxy materials for the 2024 Annual Meeting, the Company's Secretary must receive written notice of such proposal at the Company's principal executive offices no later than the close of business on October 7, 2024, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials. Any such proposal must (i) meet the requirements set forth in the rules and regulations of the SEC in order to be eligible for inclusion in the proxy materials for the 2024 Annual Meeting and (ii) contain the information specified in, and otherwise comply with, the Company's Amended and Restated By
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: September 27, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Executive Vice President & Chief Financial Officer